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Abstract
Background: The prevention of venous thromboembolism has been identified as a leading priority in hospital
safety. Recommended parenteral anticoagulant agents with different indications for the prevention and treatment
of venous thromboembolism include unfractionated heparin, low-molecular-weight heparins and fondaparinux.
Prescribing decisions in venous thromboembolism management may seem complex due to the large range of
clinical indications and patient types, and the range of anticoagulants available.
Methods: MEDLINE and EMBASE databases were searched to identify relevant original articles.
Results: Low-molecular-weight heparins have nearly replaced unfractionated heparin as the gold standard
antithrombotic agent. Low-molecular-weight heparins currently available in the US are enoxaparin, dalteparin, and
tinzaparin. Each low-molecular-weight heparin is a distinct pharmacological entity with different licensed
indications and available clinical evidence. Enoxaparin is the only low-molecular-weight heparin that is licensed for
both venous thromboembolism prophylaxis and treatment. Enoxaparin also has the largest body of clinical
evidence supporting its use across the spectrum of venous thromboembolism management and has been used as
the reference standard comparator anticoagulant in trials of new anticoagulants. As well as novel oral
anticoagulant agents, biosimilar and/or generic low-molecular-weight heparins are now commercially available.
Despite similar anticoagulant properties, studies report differences between the branded and biosimilar and/or
generic agents and further clinical studies are required to support the use of biosimilar low-molecular-weight
heparins. The newer parenteral anticoagulant, fondaparinux, is now also licensed for venous thromboembolism
prophylaxis in surgical patients and the treatment of acute deep-vein thrombosis; clinical experience with this
anticoagulant is expanding.
Conclusions: Parenteral anticoagulants should be prescribed in accordance with recommended dose regimens for
each clinical indication, based on the available clinical evidence for each agent to assure optimal safety and
efficacy.
Introduction
Venous thromboembolism (VTE) is a common disease
that occurs in hospitalized surgical and medical patients
and in the community [1]. In 2003, over 12 million
medical and surgical patients in the Nationwide Inpati-
ent Sample, comprising 31% of all US hospital dis-
charges for that year, were at risk of VTE and warranted
thromboprophylaxis [2]. The risk of VTE can persist for
ac o n s i d e r a b l ep e r i o do ft i m ea f t e rt h eV T E - t r i g g e r i n g
event, such as surgery, or hospitalization for an acute
medical condition [3]. The period of increased thrombo-
tic risk may be sustained by the presence of ongoing
risk factors such as malignancy or immobility [1]. In
addition, the risk of recurrent VTE is high, with nearly
one-third of patients experiencing a recurrent event
within 8 years [4]. In patients who do suffer a recurrent
VTE requiring rehospitalization, 50% of these events
occur in the first 3 months after their initial deep-vein
thrombosis (DVT) or pulmonary embolism (PE) [5].
After a VTE event, upto one-third of patients may suffer
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term morbidity due to leg pain, swelling, and the effects
of vascular insufficiency [4].
Effective prevention of VTE has therefore been identi-
fied by the Agency for Healthcare Research and Quality
as the leading priority in hospital safety practices. Hospi-
tals have the potential to reduce the clinical and eco-
nomic burden of VTE by implementing hospital-wide
protocols for the prevention and treatment of VTE. Sev-
eral guidelines are available such as those regularly
updated by the American College of Chest Physicians
(ACCP) and the International Union of Angiology (IUA)
[6-8], as well as specialty-based VTE guidelines.
A number of parenteral antithrombotic regimens are
available and recommended for the prevention and
treatment of VTE, including unfractionated heparin
(UFH), low-molecular-weight heparins (LMWHs; enoxa-
parin, dalteparin, tinzaparin), and selective anti-Xa inhi-
bitors (fondaparinux), as well as oral vitamin K
antagonists (warfarin). Due to the number and complex-
ity of indications in VTE management, the choice of
antithrombotic agent can appear complicated. In parti-
cular, differentiating between the parenteral antithrom-
botics can be confusing as expert guidelines on VTE
usually recommend one of a number of options and ‘a
LMWH’ rather than specifying which LMWH to pre-
scribe. However, LMWHs are distinct pharmacological
agents and not clinically interchangeable, as stated by
regulatory authorities including the US Food and Drug
Administration (FDA), European Medicines Agency
(EMEA), World Health Organization, ACCP, American
Heart Association, and American College of Cardiology
[6,7,9-12]. Therefore, when prescribing a LMWH for
either the prevention or treatment of VTE, the clinical
evidence for each agent must be reviewed. This review
aims to assist this decision-making process by analyzing
points of differentiation between each of the parenteral
antithrombotic agents recommended in current VTE
management guidelines.
Currently available parenteral anticoagulants for
VTE prevention and treatment
UFH has long been used as an anticoagulant in the pre-
vention and treatment of VTE. Prophylaxis with anticoa-
gulants is effective in reducing the incidence of VTE and
in treating acute VTE [6,8,13], but is inherently asso-
ciated with a risk of bleeding complications. UFH use is
also limited by the need for regular coagulation moni-
toring. Over the last 10 years, UFH has been replaced as
the reference standard anticoagulant in VTE manage-
ment by the LMWHs. Three LMWHs are currently
available in the USA: enoxaparin, dalteparin, and tinza-
parin. These LMWHs are individual pharmacological
entities and have different FDA-licensed indications and
dosing regimens. More recently, the synthetic pentasac-
charide fondaparinux has been developed and FDA
approved.
Mechanism of action
Although UFH, LMWHs, and fondaparinux are all indir-
ect anticoagulants and exert their effects through bind-
ing to the plasma cofactor antithrombin (AT) and
releasing endogenous mediators, a first point of differen-
tiation between UFH, LMWHs, and fondaparinux is
their chemical composition and mechanisms of action.
U F Hi sah e t e r o g e n e o u sm i x t u r eo fh i g h l ys u l f a t e d
mucopolysaccharides of varying lengths with molecular
weights ranging from 3,000 to 30,000 Da (mean 15,000
Da) that has been used as an anticoagulant since the
1950s. However, its mechanism of action was not
described until the 1970s. Only about one-third of the
heparin molecules contain the pentasaccharide binding
sequence required for its anticoagulant effect. By bind-
ing to AT, heparin induces a conformational change
that facilitates the binding of AT to thrombin and cata-
lyzes the inhibitory action of AT on both thrombin and
Factor Xa. Heparin subsequently dissociates from the
thrombin/AT complex and can be reutilized [14]. The
other high-molecular-weight chains with low anticoagu-
lant properties exhibit protein- and cell-binding effects
and contribute to bleeding and other side-effects of
UFH, such as thrombocytopenia and osteopenia [14].
In the 1980s, the LMWHs were produced using physi-
cal, chemical, or enzymatic depolymerization processes.
Each LMWH consists of a heterogeneous mixture of
polysaccharide chains with molecular weights ranging
from 2,000 to 9,000 Da (mean 4,000-5,500 Da, depend-
ing on the LMWH). As with UFH, the LMWHs bind to
AT and catalyze the inhibition of Factor Xa but, as the
polysaccharide chains are much smaller than those in
UFH, the majority of LMWH molecules are too short to
bridge AT to thrombin. Accordingly, LMWHs have a
much greater inhibitory effect on Factor Xa than on
thrombin. Whereas UFH has an anti-Factor Xa to anti-
Factor IIa ratio of 1:1, the corresponding ratio for the
LMWHs ranges from 2:1 to 14:1. The shorter mucopo-
lysaccharide chains also mean that the LMWHs have
reduced cell and plasma protein binding compared to
UFH. This translates clinically into a more predictable
dose-response effect and a lower potential for LMWHs
to induce effects such as heparin-induced thrombocyto-
penia. Each of the LMWH preparations has a different
m i x t u r eo fp o l y s a c c h a r i d eu n i t sd u et ot h es p e c i f i c
depolymerization process used in their manufacture, i.e.
enoxaparin by alkaline depolymerization of heparin ben-
zyl ester, dalteparin by nitrous acid depolymerization,
and tinzaparin by enzymatic degradation using hepari-
nase. This variation among the LMWHs gives rise to
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profiles of the different LMWH agents [14].
Fondaparinux is a synthetic pentasaccharide with a
molecular weight of 1,728 Da containing an AT-binding
domain modified from that found in UFH and LMWHs
to increase its affinity for AT. Fondaparinux cannot
inhibit thrombin and its anticoagulant activity is entirely
dependent on its ability to selectively inhibit Factor Xa
[15]. Fondaparinux can be differentiated further from
the polypharmacologic effects of UFH and LMWHs, as
it does not release tissue factor pathway inhibitor [16].
Use of parenteral anticoagulants throughout the
continuum of VTE care
Translation of the differences in chemical profiles of the
parenteral anticoagulants to their clinical profile is not
straightforward. Parenteral anticoagulants have different
FDA-approved indications for VTE, and there are differ-
ences in the supporting clinical evidence. Table 1 shows
that, of the LMWHs, enoxaparin is licensed for the
broadest range of VTE indications, encompassing both
the prevention and treatment of VTE, based on the
strength and depth of supporting clinical evidence. Tin-
zaparin is licensed for the treatment of VTE but not for
VTE prophylaxis in any patient group, while dalteparin
is licensed for VTE prevention but not for VTE treat-
ment other than long-term treatment in cancer patients.
Fondaparinux has received FDA approval for VTE pre-
vention after orthopedic and abdominal surgery and for
treatment of VTE (Table 1).
In-hospital VTE prophylaxis
Meta-analyses of randomized controlled clinical studies
have shown that the LMWHs are at least as safe and
effective as UFH in preventing VTE in both medical and
surgical inpatients [16,17]. In general surgery, a meta-
analysis of 51 studies involving more than 48,000
patients reported that prophylaxis with LMWHs was
associated with a significant reduction in the incidence
of clinical VTE compared to prophylaxis with UFH (p =
0.049) with a similar rate of major bleeding complica-
tions (p = 0.16) [18]. In hospitalized medical patients, a
meta-analysis of nine trials including data from 4,669
patients demonstrated that the LMWHs and UFH were
both similarly effective in reducing the incidence of
VTE, but LMWHs were associated with 52% fewer
bleeding complications than with UFH (p = 0.049) [17].
Meta-analyses are valuable to confirm the favorable
risk-to-benefit profile associated with LMWH prophy-
laxis but they include data from trials of various LMWH
preparations and cannot be used to support prescribing
decisions for an individual LMWH. For this reason, the
efficacy and safety data from the clinical studies for each
LMWH need to be reviewed. Table 2 summarizes the
key published data in the prevention of VTE for each
o ft h eL M W H sc u r r e n t l ya v a i l a b l ei nt h eU S Aa n d
fondaparinux [13,19-40].
Enoxaparin has been evaluated in multiple randomized
controlled trials in different patient populations and
against different comparators. In patients undergoing
hip replacement surgery, enoxaparin 30 mg twice daily
(bid) was associated with a lower incidence of sympto-
matic or asymptomatic VTE versus placebo (12% vs
42%; p = 0.0007) with low rates of major bleeding (2%
and 4%, respectively) [19]. Several trials comparing
enoxaparin 40 mg once daily or 30 mg bid with UFH
bid or three times daily (tid) in this patient population
demonstrated at least similar incidence rates of VTE
and major bleeding [20,21]. In one study, enoxaparin
30 mg bid was associated with a lower rate of VTE (5%
vs 12%; p = 0.03) and no increased bleeding (4% vs 6%)
compared with UFH [21]. Compared with warfarin,
enoxaparin 30 mg bid was associated with a lower inci-
dence of symptomatic VTE during hospitalization (1.1%
vs 0.3%, respectively; p = 0.0083) with major bleeding
rates of 0.3% and 0.6% [22]. In trials in patients under-
going knee replacement surgery, there was a consistently
Table 1 Food and Drug Administration-approved indications of parenteral anticoagulants available for the treatment
and prevention of venous thromboembolism in the US
Indication Enoxaparin Dalteparin Tinzaparin Fondaparinux
Prophylaxis
Hip replacement surgery Yes Yes No Yes
Knee replacement surgery Yes No No Yes
Hip fracture surgery No No No Yes
Abdominal surgery Yes Yes No Yes
Acutely ill medical patients Yes Yes No No
Treatment Yes No Yes Yes
- Inpatient DVT with/without PE -
Outpatient DVT without PE
- Inpatient DVT
with/without PE
- DVT - PE when initial therapy is
administered in the hospital
Secondary prophylaxis/extended
treatment in cancer patients
No Yes No No
DVT, deep-vein thrombosis; PE, pulmonary embolism.
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the prophylaxis of VTE
Indication/agent Ref. N Dose Comparator VTE, % Major bleeding, %
Hip replacement surgery
Enoxaparin [19] 100 30 mg bid Placebo 12 vs 42 (p = 0.0007) 2 vs 4
[20] 665 30 mg bid UFH bid 17.1 vs 19.0 3.3 vs 5.7
[21] 607 40 mg once
daily
UFH tid 15 vs 12 1 vs 6 (p = 0.014)
30 mg bid 5 vs 12 (p = 0.03) 4 vs 6
[22] 3,011 30 mg bid Warfarin 0.3 vs 1.1* (p = 0.0083) 0.6 vs 0.3
Dalteparin [23] 1,472 2,500 pre-op
and post-op,
5,000 IU once
daily
Warfarin 10.7 vs 24 (p < 0.001) 2.2 vs 0.4 (p = 0.01)
2,500 post-op,
5,000 IU once
daily
13.1 vs 24 (p < 0.001) 0.8 vs 0.4
Tinzaparin [24] 440 4,500 IU Enoxaparin 40 mg
once daily
21.7 vs 20.1 0.9 vs 1.8
Fondaparinux [25] 2,309 2.5 mg once
daily
Enoxaparin 40 mg
once daily
4 vs 9 (p < 0.0001) 4 vs 3
[26] 1,584 2.5 mg once
daily
Enoxaparin 30 mg bid 6 vs 8 2.0 vs 0.7
Knee replacement surgery
Enoxaparin [27] 670 30 mg bid Warfarin 36.9 vs 51.7 (p = 0.003) 2.1 vs 1.8
[28] 349 30 mg bid Warfarin 25.4 vs 45.5 (p = 0.0001) 5.2 vs 2.3
Fondaparinux [29] 724 2.5 mg bid Enoxaparin 30 mg bid 12.5 vs 27.8 (p < 0.001) 2.1 vs 0.2 (p = 0.006)
Hip fracture surgery
Fondaparinux [30] 1,250 2.5 mg once
daily
Enoxaparin 40 mg
once daily
8.3 vs 19.1 (p < 0.001) 2.2 vs 2.3
Abdominal surgery
Enoxaparin ENOXACAN [31] 631 40 mg once
daily
UFH tid 14.7 vs 18.2 4.1 vs 2.9
Dalteparin [13] 3,809 2,500 IU UFH bid 1.0 vs 1.1* 3.6 vs 4.8
[32] 1,957
† 5,000 IU Dalteparin 2,500 IU 6.6 vs 12.7 (p < 0.001) 1.3 vs 0.3
Fondaparinux [33] 2,048 2.5 mg once
daily
Dalteparin 2,500 pre-
op and post-op, 5,000
IU once daily
4.6 vs 6.1 (p = 0.144) 3.4 vs 2.4 (p = 0.122)
Acutely ill medical inpatients
Enoxaparin MEDENOX [34] 866 40 mg once
daily
Placebo 5.5 vs 14.9 (p < 0.001) 3.4 vs 2.0
[35] 959 40 mg once
daily
UFH tid 0.2 vs 1.4* 0.4 vs 1.5
[36] 451 40 mg once
daily
UFH tid 8.4 vs 10.4 (p = 0.015 for equivalence) 0.3 vs 0.3
[37] 212 40 mg once
daily
UFH 5,000 U tid 19.7 vs 34.7 (p = 0.044) 2.8 vs 1.9
[38] 1,762 40 mg once
daily
UFH 5,000 U bid 10 vs 18 (p = 0.0001) 1 vs 0 (p = 0.015)
Dalteparin PREVENT [39] 3,706 5,000 IU Placebo 2.77 vs 4.96 (p = 0.0015) 0.49 vs 0.16 (p = 0.15)
Fondaparinux ARTEMIS [40] 849 2.5 mg once
daily
Placebo 5.6 vs 10.5 (p = 0.029) 0.2 vs 0.2
*Incidence of symptomatic VTE diagnosed during hospitalization.
†Intent-to-treat population.
bid, twice daily; tid, three times daily; UFH, unfractionated heparin; VTE, venous thromboembolism.
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with warfarin with no significant increase in the rate of
major bleeding [27,28]. In patients undergoing abdom-
inal or pelvic surgery for cancer, enoxaparin 40 mg once
daily was as effective and safe as UFH administered tid
[31]. In acutely ill medical patients, the incidence of
symptomatic or non-symptomatic VTE was lower with
enoxaparin 40 mg once daily than with placebo (5.5% vs
14.9%; p < 0.001) with no significant increase in major
bleeding (3.4% vs 2.0%) [34]. Enoxaparin 40 mg once
daily was as safe and effective as UFH 5000U tid [35,36].
In patients with acute ischemic stroke, the risk of symp-
tomatic or asymptomatic VTE with enoxaparin 40 mg
once daily was lower compared to that with UFH 5,000
U bid (10% vs 18%; p = 0.001), with a similar risk of
symptomatic intracranial bleeding (1% vs 1%; p = 0.55)
and a higher rate of major extracranial bleeding (1% vs
0; p = 0.015) [38] (Table 2).
Dalteparin has also been evaluated for the prevention
of VTE. In patients undergoing hip replacement surgery,
dalteparin 5,000 IU once daily was associated with a
lower incidence of VTE compared with warfarin (11.9%
vs 24.0%; p < 0.001), while major bleeding was higher
with preoperative initiation of dalteparin (2.2% vs 0.4%;
p = 0.01) but not postoperative initiation (0.8% vs 0.4%)
[23]. In abdominal surgery, dalteparin 2,500 IU was as
safe and effective as UFH bid [13]. In acutely ill medical
patients, the incidence of symptomatic or asymptomatic
VTE was lower with dalteparin 5,000 IU versus placebo
(2.77% vs 4.96%; p = 0.0015) with no significant increase
in major bleeding (0.49% vs 0.16%; p = 0.15) [39]. Few
randomized controlled trials have evaluated the off-label
use of tinzaparin in the prevention of VTE [24] (Table 2).
Trials with fondaparinux 2.5 mg once daily in hip
replacement surgery demonstrated a lower incidence of
VTE when compared with enoxaparin 40 mg once daily
[25], but an equivalent incidence compared with enoxa-
parin 30 mg bid [26], while reporting no significant dif-
ference in the incidence of major bleeding. In knee
replacement surgery, fondaparinux 2.5 mg bid was asso-
ciated with a lower incidence of asymptomatic or symp-
tomatic VTE compared with enoxaparin 30 mg bid
(12.5% vs 27.8%; p < 0.001), at the expense of an
increase in major bleeding complications (2.1% vs 0.2%;
p = 0.006) [29]. In hip fracture surgery, fondaparinux
2.5 mg once daily was compared with enoxaparin 40 mg
once daily, and showed a lower rate of VTE (8.3% vs
19.1%; p < 0.001) with no significant difference in major
bleeding rates (2.2% vs 2.3%; p = 1.0) [30]. In a meta-
analysis of 4 trials in major orthopedic surgery patients,
the incidence of symptomatic or asymptomatic VTE
with fondaparinux was lower compared with enoxaparin
(6.8% vs 13.7%; p < 0.001) with an increase in major
bleeding events (2.7% vs 1.7%; p = 0.008) [41].
Fondaparinux 2.5 mg once daily in patients undergoing
abdominal surgery was associated with similar rates of
VTE (4.6% vs 6.1%; p = 0.144) and major bleeding (3.4%
vs 2.4%; p = 0.122) compared with dalteparin 5,000 IU
started preoperatively at a dose of 2,500 IU [33]. In
acutely ill medical patients at risk of VTE, fondaparinux
was associated with a lower incidence of asymptomatic
or symptomatic VTE compared with placebo (5.6% vs
10.5%; p = 0.029) and did not increase major bleeding
(0.2% vs 0.2%) [40] (Table 2).
Extended-duration thromboprophylaxis
It has been reported that more than two-thirds of all
symptomatic VTE events occur in the outpatient setting,
predominantly in patients who have recently undergone
surgery or been hospitalized for medical illness [3]. In fact,
47% and 76% of all clinical VTE events related to hip or
knee replacement, respectively, occur post-discharge [42].
Currently, both the ACCP and IUA guidelines recommend
prophylaxis extended beyond hospitalization to up to
35 days in specific patient groups, such as patients under-
going major elective orthopedic surgical procedures or
major surgery for cancer [6,8].
The majority of the available clinical evidence for the
use of LMWHs as extended-duration prophylaxis is
with enoxaparin. In orthopedic surgery, three rando-
mized, double-blind placebo-controlled trials have
shown that a lower incidence of VTE can be achieved
by extending the duration of prophylaxis with enoxa-
parin to 4 weeks postoperatively, without an increasing
in the number of bleeding complications or other
adverse events [43-45]. Similarly, a double-blind rando-
mized controlled study in patients undergoing major
surgery for abdominal or pelvic cancer has shown that 4
weeks of prophylaxis with enoxaparin 40 mg once daily
is significantly more effective in reducing VTE than 1
week of enoxaparin prophylaxis (4.8% vs 12.0%; p =
0.02) with no increase in major bleeding (0.8% vs 0.4%;
p>0 . 9 9 ) ;t h i sb e n e f i tw a ss u s t a i n e dd u r i n ga3 - m o n t h
follow-up period [46].
Dalteparin has been evaluated for extended-duration
prophylaxis in surgical patients; two double-blind pla-
cebo-controlled studies have shown a lower incidence
of late VTE with dalteparin in patients undergoing total
hip replacement surgery without increasing major
bleeding [47,48]. A small study (n = 176) on extended-
duration prophylaxis with tinzaparin after general sur-
gery failed to demonstrate a significant difference
between 1 and 4 weeks of prophylaxis (VTE incidence
5.2% vs 10%; p = 0.49) and reported similar rates of
bleeding (2/58 vs 3/60) [49].
Fondaparinux has been shown to be effective as
extended-duration prophylaxis after major orthopedic
surgery in two trials. The placebo-controlled PENTHI-
FRA study reported that in patients who had undergone
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laxis with fondaparinux for 3 weeks was associated with
a lower risk of symptomatic VTE (0.3% vs placebo 2.7%;
p = 0.02) with an increase in major bleeding complica-
tions bordering significance (2.4% vs 0.6%; p = 0.06)
[50]. Similarly, 3-5 weeks of extended-duration VTE
prophylaxis with fondaparinux was shown to be effective
and have a good safety profile after major lower limb
surgery in patients with or without indwelling neuraxial
or deep peripheral nerve catheters [51].
Treatment of VTE
Current ACCP guidelines recommend LMWH, UFH, or
fondaparinux for the short-term treatment of objectively
confirmed VTE [7]. Treatment with a LMWH given sub-
cutaneously once daily or bid is recommended over UFH,
on an outpatient basis if possible, and as an inpatient if
necessary [7]. A number of clinical studies [52-57] and a
meta-analysis [58] have demonstrated that the LMWHs
are superior or non-inferior to UFH in preventing VTE
recurrence (pooled relative risk [RR] 0.85, 95% confidence
interval [CI]: 0.65-1.12; N = 4,447) and the incidence of
bleeding events (pooled RR 0.63, 95% CI: 0.37-1.05; N =
4,447), and superior to UFH in terms of improved survival
(pooled RR 0.76, 95% CI: 0.59-0.98; N = 4,033) [58]. The
key clinical studies of each of the LMWHs in the treat-
ment of VTE [52-57] are shown in Table 3 [52-57,59-61].
Enoxaparin is the only LMWH currently licensed in
the US for outpatient treatment of acute DVT (without
PE) in conjunction with oral warfarin (Table 1). A meta-
analysis of studies of enoxaparin outpatient treatment
including more than 1,500 patients with DVT, with or
without PE, reported that enoxaparin is as effective in
terms of VTE recurrence, major bleeding, and death as
inpatient treatment with UFH [62]. The presence of
symptomatic PE does not appear to affect the outcomes
of DVT treatment with enoxaparin [62]. Furthermore,
enoxaparin continued beyond the initial treatment of
DVT offers benefits; an analysis of outpatient treatment
of VTE with enoxaparin found that outpatient treatment
with a combination of enoxaparin and warfarin was
associated with 26% (p < 0.05) fewer hospital readmis-
sions for recurrent DVT or PE compared to patients
treated with warfarin alone. This was associated with an
overall saving of USD 1,151 per patient in total DVT-
treatment-related costs over warfarin monotherapy [63].
Although clinical data are available for dalteparin in
the treatment of VTE [53], it is not licensed by the FDA
for VTE treatment other than long-term treatment in
cancer patients (Table 1). The CLOT trial reported that
long-term prophylaxis with dalteparin in patients with
cancer and DVT was associated with a significantly
lower incidence of VTE recurrence compared to oral
anticoagulant therapy with no increase in bleeding com-
plications [64]. Based on the findings of the CLOT trial
[64], dalteparin is licensed for extended-duration pro-
phylaxis in patients with cancer as a regimen of anti-
Factor Xa 200 IU/kg once daily for 1 month followed by
anti-Factor-Xa 150 IU/kg for an additional 5 months.
Table 3 Evidence from clinical trials of the efficacy and safety of parenteral anticoagulants in the treatment of VTE
Indication/agent Ref. N Dose Patients Comparator Recurrent
VTE, %
Major
bleeding,
%
Inpatient VTE treatment
Enoxaparin [52] 900 1.5 mg/kg once daily DVT with/
without PE
IV UFH 4.4 vs 4.1* 1.7 vs 2.1*
1.0 mg/kg bid 2.9 vs 4.1* 1.3 vs 2.1*
Dalteparin [53] 204 200 IU/kg once daily DVT IV UFH 5.0 vs 2.9 0 vs 0
[54] 253 200 IU/kg once daily DVT IV UFH 3.6 vs 1.7 0 vs 1.5
Tinzaparin THESEE
[55]
612 175 IU/kg once daily PE IV UFH 1.6 vs 1.9* 2.0 vs 2.6*
Fondaparinux MATISSE
[59]
2,213 5 mg (body weight <50 kg), 7.5 mg (50-100
kg), or 10 mg (>100 kg)
PE IV UFH 3.8 vs 5.0* 2.0 vs 2.4*
[60] 2,205 5 mg (body weight <50 kg), 7.5 mg (50-100
kg), or 10 mg (>100 kg)
DVT Enoxaparin 1.0 mg/
kg bid
3.9 vs 4.1* 2.6 vs 2.4*
Outpatient treatment
Enoxaparin [56] 500 1.0 mg/kg bid DVT IV UFH (inpatient) 5.3 vs 6.7 2.0 vs 1.2
[61] 298 1.5 mg/kg once daily DVT IV UFH (inpatient) 2.7 vs 8.8
(p = 0.026)
0 vs 2.0
Tinzaparin [57] 505 175 IU/kg once daily DVT and/or
PE
Dalteparin 200 IU/
kg once daily
3.9 vs 3.6 2.0 vs 0.8
*Non-inferior.
bid, twice daily; DVT, deep-vein thrombosis; IV, intravenous; PE, pulmonary embolism; UFH, unfractionated heparin; VTE, venous thromboembolism.
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DVT with or without PE [51] (Table 1). A study com-
paring tinzaparin 175 IU once daily with dalteparin 200
IU once daily for outpatient treatment of DVT and/or
PE reported no significant difference in the incidence of
recurrent VTE or major bleeding between the two
LMWHs [57].
Fondaparinux is licensed for the outpatient treatment
of DVT, and of PE if initial treatment takes place in the
hospital (Table 1). Non-inferiority for VTE recurrence
and major bleeding was demonstrated compared to
UFH in the treatment of PE [59] and compared to enox-
aparin in the treatment of DVT [60].
Differentiation between branded and biosimilar
LMWHs
Biosimilar versions of enoxaparin have been developed
and being marketed as generic equivalents and clinically
used in India and South America, and initial regulatory
approval of a biosimilar formulation of enoxaparin was
granted in Canada [65]. In July 2010, the US FDA
approved a generic version of enoxaparin [Sandoz, a
division of Novartis group] utilizing the generic drug
pathway. On the other hand, the EMEA has considered
these agents to be biosimilar. Furthermore, the EMEA
stated that biosimilar versions of LMWHs should be
considered biological medicinal products and may not
be submitted for approval as generic medicinal products.
In a concept guideline manuscript, the EMEA considers
the heterogeneity of LMWH to be very high, and
recommends clinical trials to demonstrate equivalence
of biosimilar LMWHs [11]. Thus there is a regulatory
discordance between the EMEA and US FDA.
As the biosimilar LMWHs have only recently been
produced there is limited clinical data available with
which to compare the biosimilar and branded versions.
The available data from pharmacological in vitro or pre-
clinical studies using anticoagulation profiles and neu-
tralization with protamine sulfate as their primary
outcomes differentiate branded from biosimilar
LMWHs. Biosimilar and branded versions of enoxaparin
[66,67] and dalteparin [67] differ in their responses to
the inhibitor protamine sulfate, the composition of their
oligosaccharide chains [66,67], their affinity for AT [67],
and their immunogenic potential [68]. The differences
in assay-responses become more pronounced at higher
concentrations: for example, at prophylactic doses the
anticoagulant levels of the branded and biosimilar enox-
aparin appear similar but at treatment doses enoxaparin
exhibits significantly greater anticoagulant effects [66].
Similar dose-dependent variations have been reported in
the response to neutralization with protamine sulfate
[67].
Anticoagulants in development
(Ultra-)LMWHs are currently being developed for dif-
ferent indications, amongst others bemiparin (Rovi,
Madrid, Spain) and semuloparin (sonofi-aventis, Paris,
France). Due to the clinical and practical limitations of
warfarin, new oral anticoagulants to replace warfarin
have also been sought. Oral vitamin K antagonists (war-
farin) are used for long-term anticoagulation [6,7]. The
first of the new oral anticoagulants was the oral direct
thrombin inhibitor ximelagatran. However, this drug
was withdrawn from use soon after it was licensed due
to evidence of its potential hepatotoxicity. Two second-
generation direct oral Factor Xa inhibitors–rivaroxaban,
which has been approved in the EU and Canada, and
apixaban–are currently in the final stages of clinical
development. Based on the ximelagatran experience,
clinical vigilance is required to determine the long-term
safety of these agents. Dabigatran is another novel oral
anticoagulant which has received recent approval in
some European countries, Canada and recently in US;
dabigatran is a direct thrombin inhibitor, administered
orally as a double prodrug formulation (dabigatran etex-
ilate). However, while this drug is approved in EMEA
for post orthopedic surgical thromboprophylaxis, in the
US, it is approved for stroke prevention in atrial fibrilla-
tion. Several other oral anticoagulants such as edoxaban,
betrixiban are also in clinical development. A parenteral
anti Xa agent with strong anticoagulant activity namely
Otamixaban (sonofi-aventis, Paris, France) is also in
advanced clinical stages as a parenteral anticoagulant in
percutaneous intervention.
New anticoagulants completing clinical development
are not supported by the depth of clinical evidence that
is available for the currently recommended anticoagu-
lants in terms of clinical experience or the range of
patient populations and indications. Many issues remain
to be elucidated, such as long-term safety, drug initia-
tion, reversal of anticoagulation, and the appropriate
bridging protocol from parenteral agents.
Conclusions
The use of antithrombotic agents in VTE management
spans a continuum ranging from VTE prevention using
prophylaxis of appropriate duration for at-risk patients
to timely treatment of VTE. Ideally, an antithrombotic
drug should have clinically proven efficacy with a good
safety profile in both the prevention and treatment of
VTE for a wide range of patient types. Each of the
LMWHs is a distinct drug, with unique clinical pharma-
cokinetics and pharmacodynamics, and LMWHs cannot
be prescribed interchangeably. LMWHs should be pre-
scribed in accordance with recommended dose regimens
for each licensed clinical indication, based on the
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Page 7 of 10available clinical evidence for each agent. The newer
parenteral anticoagulant, fondaparinux, is now also
licensed for VTE prophylaxis in surgical patients and
the treatment of acute DVT; clinical experience with
this anticoagulant is expanding. In contrast to the
LMWHs, fondaparinux does not exhibit polypharmaco-
logic action although thrombosis is a polypathologic
process. Generic versions of the branded LMWHs are
now available for clinical use. However, because of the
intra-class heterogeneity of LMWHs, each LMWH
needs to be supported by clinical evidence of its efficacy
and safety profile. Of the currently available antithrom-
botics, the LMWH enoxaparin offers the most extensive
clinical experience and the widest range of clinical indi-
cations including surgical and medical thromboprophy-
laxis, and inpatient and outpatient treatment of VTE.
Besides the LMWHs, several ultra-LMWHs are cur-
rently being developed for different indications. There-
fore, this class of drug will continue to have a major
impact in the future management of thrombosis. The
newly developed oral antithrombin and anti-Xa agents
are mono-therapeutic and will require clinical validation
in specific indications.
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